The pending acquisition by Merck KGaA is the dominant corporate event; monitor shareholder vote and regulatory approvals for closing in Q1 2027. The Q3 results are largely backward-looking and overshadowed by the acquisition.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $19.80entry
- T+1 · 4d ago +0.15%α +0.51% · $19.83
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Silence Therapeutics reported Q3 2026 results showing a reduced net loss of $12.4M ($0.08/share) versus $21.0M ($0.15/share) a year ago, driven by lower R&D and G&A expenses. The company also highlighted its definitive agreement to be acquired by Merck KGaA, expected to close in Q1 2027, and positive Phase 2 data for divesiran. The filing is a DEFA14A furnishing the earnings press release and solicitation materials related to the pending acquisition.
Key Financial Metrics
Key Facts
- Net loss for Q3 2026 was $12.4M ($0.08 per share), compared to $21.0M ($0.15 per share) in Q3 2025.
- Cash and cash equivalents were $247.7M as of September 30, 2026, including $201.3M from an upsized public offering.
- R&D expenses decreased to $9.3M from $20.5M year-over-year.
- G&A expenses decreased to $4.9M from $5.8M year-over-year.
- On October 19, 2026, Silence entered into a definitive agreement to be acquired by Merck KGaA, expected to close in Q1 2027.
- Positive Phase 2 SANRECO trial results for divesiran in polycythemia vera reported on August 10, 2026.
- Total outstanding shares were 186,609,073 as of September 30, 2026.
Financial Impact
Net loss improved by $8.5M year-over-year; cash position strengthened by $236.4M from year-end 2025.
Risk Factors
- Acquisition may not close due to failure to obtain regulatory or shareholder approvals, or other customary conditions.
- Shareholder litigation could delay or derail the transaction.
- Competing acquisition proposals could emerge.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-457070 |
| Document: 0001193125-26-457070-index-headers.html | 0001193125-26-457070 |
| Document: 0001193125-26-457070-index.html | 0001193125-26-457070 |
| Document: 0001193125-26-457070.txt | 0001193125-26-457070 |
Track record
15 reports on SLN
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago DEFA14A Neutral 4/10 Viewing Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers